The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.66 billion in 2024 to $19.27 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to vaccine development, antiviral medications, public health initiatives, research funding, emerging therapies.
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $22.75 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination.
The hepatitis therapeutic market is anticipated to experience growth due to the global rise in hepatitis infections. The surge in hepatitis cases can be attributed to factors such as inadequate access to healthcare and vaccinations, increased intravenous drug use, unsafe blood transfusion practices, and suboptimal sanitation and hygiene conditions in certain regions. As of April 2022, the World Health Organization (WHO) reported at least 169 cases of acute hepatitis of unknown origin in 11 nations, with an estimated 350 million individuals worldwide affected by viral hepatitis B or C. However, for the majority of affected individuals, testing and treatment remain inaccessible. Consequently, the hepatitis therapeutics market is expanding in response to the escalating prevalence of hepatitis infections.
The increasing number of clinical trials is expected to drive the growth of the hepatitis therapeutic market in the future. Clinical trials are research studies that assess new treatments, medications, or interventions in human participants. They are essential for developing new hepatitis therapeutics, providing a rigorous and ethical framework for evaluating the safety and efficacy of potential treatments, and ensuring that patients have access to the most effective therapies available. For instance, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, reported a slight increase of 4.3% in the total number of industry-initiated clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Therefore, the rising number of clinical trials is contributing to the growth of the hepatitis therapeutics market.
A key trend in the hepatitis therapeutics market is the emergence of product innovations. Major companies in the market are actively involved in developing new products to maintain their market position. In November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company, obtained FDA approval for Vemlidy (tenofovir alafenamide) to treat pediatric patients with chronic hepatitis B virus infection. Vemlidy, a targeted prodrug of tenofovir, was initially approved in 2016 as a once-daily treatment for chronic hepatitis B virus infection and compensated liver disease in adults. It is recognized as a preferred or first-line treatment according to recommendations from the American Liver Foundation.
Strategic agreements have become a focal point for major companies operating in the hepatitis therapeutics market, aimed at gaining a competitive edge. In October 2023, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced an exclusive licensing agreement for JNJ-3989, an investigational subcutaneous RNA interference therapeutic designed for treating chronic hepatitis B (CHB). JNJ-3989 is an innovative RNA interference therapeutic targeting the hepatitis B virus (HBV) X protein, which is crucial for HBV replication and persistence.
In February 2024, Gilead Sciences Inc., a pharmaceutical company based in the United States, acquired Cymabay Therapeutics, Inc., for an undisclosed sum. This acquisition is intended to strengthen Gilead's liver disease portfolio by incorporating seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to meet unmet medical needs and enhance treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the US that specializes in developing innovative therapies for chronic diseases, particularly those affecting the liver and diabetes.
Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.
North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hepatitis denotes inflammation of the liver caused by various viruses and non-viral factors. Hepatitis therapeutics encompasses medications designed to treat all forms of hepatitis, with immune modulators and oral antivirals being the primary drugs employed.
The principal disease types addressed through hepatitis therapeutics include hepatitis A, hepatitis B, hepatitis C, and other related conditions. Hepatitis A involves liver inflammation that can manifest as mild to severe illness. These therapeutics are categorized based on drug class into oral antivirals and immune modulators, with distribution channels extending to hospital pharmacies, drug stores, retail pharmacies, and online providers.
The hepatitis therapeutics market research report is one of a series of new reports that provides hepatitis therapeutics optical components market statistics, including hepatitis therapeutics optical components industry global market size, regional shares, competitors with a hepatitis therapeutics optical components market share, detailed hepatitis therapeutics optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics optical components industry. This hepatitis therapeutics optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $22.75 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination.
The hepatitis therapeutic market is anticipated to experience growth due to the global rise in hepatitis infections. The surge in hepatitis cases can be attributed to factors such as inadequate access to healthcare and vaccinations, increased intravenous drug use, unsafe blood transfusion practices, and suboptimal sanitation and hygiene conditions in certain regions. As of April 2022, the World Health Organization (WHO) reported at least 169 cases of acute hepatitis of unknown origin in 11 nations, with an estimated 350 million individuals worldwide affected by viral hepatitis B or C. However, for the majority of affected individuals, testing and treatment remain inaccessible. Consequently, the hepatitis therapeutics market is expanding in response to the escalating prevalence of hepatitis infections.
The increasing number of clinical trials is expected to drive the growth of the hepatitis therapeutic market in the future. Clinical trials are research studies that assess new treatments, medications, or interventions in human participants. They are essential for developing new hepatitis therapeutics, providing a rigorous and ethical framework for evaluating the safety and efficacy of potential treatments, and ensuring that patients have access to the most effective therapies available. For instance, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, reported a slight increase of 4.3% in the total number of industry-initiated clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Therefore, the rising number of clinical trials is contributing to the growth of the hepatitis therapeutics market.
A key trend in the hepatitis therapeutics market is the emergence of product innovations. Major companies in the market are actively involved in developing new products to maintain their market position. In November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company, obtained FDA approval for Vemlidy (tenofovir alafenamide) to treat pediatric patients with chronic hepatitis B virus infection. Vemlidy, a targeted prodrug of tenofovir, was initially approved in 2016 as a once-daily treatment for chronic hepatitis B virus infection and compensated liver disease in adults. It is recognized as a preferred or first-line treatment according to recommendations from the American Liver Foundation.
Strategic agreements have become a focal point for major companies operating in the hepatitis therapeutics market, aimed at gaining a competitive edge. In October 2023, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced an exclusive licensing agreement for JNJ-3989, an investigational subcutaneous RNA interference therapeutic designed for treating chronic hepatitis B (CHB). JNJ-3989 is an innovative RNA interference therapeutic targeting the hepatitis B virus (HBV) X protein, which is crucial for HBV replication and persistence.
In February 2024, Gilead Sciences Inc., a pharmaceutical company based in the United States, acquired Cymabay Therapeutics, Inc., for an undisclosed sum. This acquisition is intended to strengthen Gilead's liver disease portfolio by incorporating seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to meet unmet medical needs and enhance treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the US that specializes in developing innovative therapies for chronic diseases, particularly those affecting the liver and diabetes.
Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.
North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hepatitis denotes inflammation of the liver caused by various viruses and non-viral factors. Hepatitis therapeutics encompasses medications designed to treat all forms of hepatitis, with immune modulators and oral antivirals being the primary drugs employed.
The principal disease types addressed through hepatitis therapeutics include hepatitis A, hepatitis B, hepatitis C, and other related conditions. Hepatitis A involves liver inflammation that can manifest as mild to severe illness. These therapeutics are categorized based on drug class into oral antivirals and immune modulators, with distribution channels extending to hospital pharmacies, drug stores, retail pharmacies, and online providers.
The hepatitis therapeutics market research report is one of a series of new reports that provides hepatitis therapeutics optical components market statistics, including hepatitis therapeutics optical components industry global market size, regional shares, competitors with a hepatitis therapeutics optical components market share, detailed hepatitis therapeutics optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics optical components industry. This hepatitis therapeutics optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hepatitis Therapeutics Market Characteristics3. Hepatitis Therapeutics Market Trends and Strategies4. Hepatitis Therapeutics Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Hepatitis Therapeutics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Hepatitis Therapeutics Market34. Recent Developments in the Hepatitis Therapeutics Market
5. Global Hepatitis Therapeutics Growth Analysis and Strategic Analysis Framework
6. Hepatitis Therapeutics Market Segmentation
7. Hepatitis Therapeutics Market Regional and Country Analysis
8. Asia-Pacific Hepatitis Therapeutics Market
9. China Hepatitis Therapeutics Market
10. India Hepatitis Therapeutics Market
11. Japan Hepatitis Therapeutics Market
12. Australia Hepatitis Therapeutics Market
13. Indonesia Hepatitis Therapeutics Market
14. South Korea Hepatitis Therapeutics Market
15. Western Europe Hepatitis Therapeutics Market
16. UK Hepatitis Therapeutics Market
17. Germany Hepatitis Therapeutics Market
18. France Hepatitis Therapeutics Market
19. Italy Hepatitis Therapeutics Market
20. Spain Hepatitis Therapeutics Market
21. Eastern Europe Hepatitis Therapeutics Market
22. Russia Hepatitis Therapeutics Market
23. North America Hepatitis Therapeutics Market
24. USA Hepatitis Therapeutics Market
25. Canada Hepatitis Therapeutics Market
26. South America Hepatitis Therapeutics Market
27. Brazil Hepatitis Therapeutics Market
28. Middle East Hepatitis Therapeutics Market
29. Africa Hepatitis Therapeutics Market
30. Hepatitis Therapeutics Market Competitive Landscape and Company Profiles
31. Hepatitis Therapeutics Market Other Major and Innovative Companies
35. Hepatitis Therapeutics Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Hepatitis Therapeutics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hepatitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hepatitis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Disease Type: Hepatitis a; Hepatitis B; Hepatitis C; Other Disease Types2) by Drug Class: Oral Antivirals; Immune Modulators
3) by Distribution Channel: Hospital Pharmacies; Drug Stores and Retail Pharmacies; Online Providers
Subsegments:
1) by Hepatitis a: Vaccines; Post-Exposure Prophylaxis (PEP)2) by Hepatitis B: Antiviral Medications; Immune Modulators; Vaccines
3) by Hepatitis C: Direct-Acting Antivirals (DAAs); Ribavirin; Interferon-Based Therapies
4) by Other Disease Types: Hepatitis D; Hepatitis E; Other Viral Hepatitis Infections
Key Companies Mentioned: Gilead Sciences Inc.; Bristol-Myers Squibb Co.; AbbVie Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Hepatitis Therapeutics market report include:- Gilead Sciences Inc.
- Bristol-Myers Squibb Co.
- AbbVie Inc.
- Merck & Co. Inc.
- Johnson & Johnson Services Inc.
- Cipla Inc.
- F Hoffmann-La Roche Ltd.
- Biocon Limited
- LAURUS Labs Ltd.
- Zydus Lifesciences Limited
- Hetero Healthcare Limited
- Novartis AG
- Sanofi SA
- GlaxoSmithKline plc
- Lupin Ltd.
- Teva Pharmaceutical Industries Ltd.
- NATCO Pharma Limited
- Pfizer Inc.
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Biocon Biopharmaceuticals Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 19.27 Billion |
| Forecasted Market Value ( USD | $ 22.75 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
